crisprtherapeutics
CRISPR Therapeutics stock may offer an intriguing opportunity for investors with a long time horizon Shares of CRISPR Therapeutics (NASDAQ:CRSP) are up 4% in 2022. And long-term shareholders who have held their shares in CRSP stock for the last five years have been rewarded with a gain of over 330%. However, the stock is trading nearly 50% below its 52-week high. That means, if you were a shareholder that got in on CRSP stock near its peak, you could have a negative opinion of the stock. Q2 2022 hedge fund letters, conferences and more That's the nature of speculative stocks in areas like gene...
ValueWalk
Crispr Therapeutics AG (NASDAQ:CRSP) is a Swiss-American gene editing biotech company developing gene-based medicines. The company’s technology targets specific DNA sequences to modify, delete or correct them. The company’s platform focuses primarily on ex-Vivo programs that target sickle cell disease, β-thalassemia and B-cell malignancies. The lead program targeting sickle cell disease and β-thalassemia has entered clinical testing. Q1 2022 hedge fund letters, conferences and more CRSP shares fell from a January 2021 high of $220.20 per share in Jan. 2021 but shed 27% this year. The shares fo...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら